Topics

AML Findings Suggest a Broader Role for Genomic Testing

13:12 EDT 15 Aug 2019 | OncLive

Genomic profiling provides evidence of measurable residual disease in patients with acute myeloid leukemia and may help guide the choice of a preconditioning regimen in those who are at risk of relapse after undergoing allogeneic hematopoietic cell transplantation.

Original Article: AML Findings Suggest a Broader Role for Genomic Testing

NEXT ARTICLE

More From BioPortfolio on "AML Findings Suggest a Broader Role for Genomic Testing"

Quick Search